Helmholtz Gemeinschaft

Search
Browse
Statistics
Feeds

Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica

[img]
Preview
PDF - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
1MB
[img] Other (Supplementary Information)
604kB

Item Type:Article
Title:Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica
Creators Name:Waters, P. and Reindl, M. and Saiz, A. and Schanda, K. and Tuller, F. and Kral, V. and Nytrova, P. and Sobek, O. and Nielsen, H.H. and Barington, T. and Lillevang, S.T. and Illes, Z. and Rentzsch, K. and Berthele, A. and Berki, T. and Granieri, L. and Bertolotto, A. and Giometto, B. and Zuliani, L. and Hamann, D. and van Pelt, E.D. and Hintzen, R. and Höftberger, R. and Costa, C. and Comabella, M. and Montalban, X. and Tintoré, M. and Siva, A. and Altintas, A. and Deniz, G. and Woodhall, M. and Palace, J. and Paul, F. and Hartung, H.P. and Aktas, O. and Jarius, S. and Wildemann, B. and Vedeler, C. and Ruiz, A. and Leite, M.I. and Trillenberg, P. and Probst, M. and Saschenbrecker, S. and Vincent, A. and Marignier, R.
Abstract:OBJECTIVE: Antibodies to cell surface central nervous system proteins help to diagnose conditions which often respond to immunotherapies. The assessment of antibody assays needs to reflect their clinical utility. We report the results of a multicentre study of aquaporin (AQP) 4 antibody (AQP4-Ab) assays in neuromyelitis optica spectrum disorders (NMOSD). METHODS: Coded samples from patients with neuromyelitis optica (NMO) or NMOSD (101) and controls (92) were tested at 15 European diagnostic centres using 21 assays including live (n=3) or fixed cell-based assays (n=10), flow cytometry (n=4), immunohistochemistry (n=3) and ELISA (n=1). RESULTS: Results of tests on 92 controls identified 12assays as highly specific (0-1 false-positive results). 32 samples from 50 (64%) NMO sera and 34 from 51 (67%) NMOSD sera were positive on at least two of the 12 highly specific assays, leaving 35 patients with seronegative NMO/spectrum disorder (SD). On the basis of a combination of clinical phenotype and the highly specific assays, 66 AQP4-Ab seropositive samples were used to establish the sensitivities (51.5-100%) of all 21 assays. The specificities (85.8-100%) were based on 92 control samples and 35 seronegative NMO/SD patient samples. CONCLUSIONS: The cell-based assays were most sensitive and specific overall, but immunohistochemistry or flow cytometry could be equally accurate in specialist centres. Since patients with AQP4-Ab negative NMO/SD require different management, the use of both appropriate control samples and defined seronegative NMOSD samples is essential to evaluate these assays in a clinically meaningful way. The process described here can be applied to the evaluation of other antibody assays in the newly evolving field of autoimmune neurology.
Keywords:Aquaporin 4, Autoantibodies, Enzyme-Linked Immunosorbent Assay, Immunohistochemistry, Neuromyelitis Optica, Sensitivity and Specificity
Source:Journal of Neurology Neurosurgery and Psychiatry
ISSN:0022-3050
Publisher:BMJ Publishing Group
Volume:87
Number:9
Page Range:1005-1015
Date:September 2016
Additional Information:Copyright: Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Official Publication:https://doi.org/10.1136/jnnp-2015-312601
PubMed:View item in PubMed

Repository Staff Only: item control page

Downloads

Downloads per month over past year

Open Access
MDC Library